Abstract
Introduction: Clinical manifestations of coronavirus disease-2019 (COVID-19) range from asymptomatic to severe clinical forms. Factors contributing to the unfavorable disease course, including gender and age of the patients, are still being studied. Aim: The aim of the study is to assess the age and gender specifics of patients with different COVID-19 severity in the period March - December 2020 in the Autonomous Province of Vojvodina. Material and methods: A descriptive method was applied. Data on laboratory-confirmed cases of COVID-19 were retrieved from the surveillance database of the Institute of Public Health of Vojvodina and analyzed retrospectively. In terms of disease severity, cases were classified as: asymptomatic, mild, severe or critical. The gender and age-specific characteristics of COVID-19 cases in relation to the severity of the disease were analyzed and presented in tables and graphs. Results: In the observed period, a total of 78106 COVID-19 cases were registered (incidence 4217/100.000). Females accounted for 50.8% of cases. The highest age-specific incidence was registered in the age group 30 - 59 years (5876/100.000). Severe and critical forms of COVID-19 were more common in patients aged ≥ 60 years (18.0 - 39.0%). The asymptomatic disease prevailed in elderly ≥ 80 years (16.0%) and children < 9 years of age (13.0%). The specific incidence of severe/critical forms was 1.6 - 2.4 times higher in men. Conclusion: In the early phase of the COVID-19 pandemic, disease severity varied according to the gender and age of the patients. The working-age population was largely affected but severe disease forms were more often registered in the oldest, mostly male, patients.
Publisher
Centre for Evaluation in Education and Science (CEON/CEES)
Reference23 articles.
1. Guo YR, Cao QD, Hong ZS, Tan YY, Chen SD, Jin HJ, et al. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak -an update on the status. Mil Med Res. 2020; 7(1):11;
2. World Health Organisation. The impact of COVID-19 on global health goals [updated 2021 May 20; cited 2022 January 20];
3. Ristić M, Milosavljević B, Vapa S, Marković M, Petrović V. Seroprevalence of antibodies against SARS-CoV-2 virus in Northern Serbia (Vojvodina): A four consecutive sentinel population-based survey study. PLoS One. 2021; 16(7):e0254516;
4. Cascella M, Rajnik M, Aleem A, Dulebohn SC, Di Napoli R. Features, Evaluation, and Treatment of Coronavirus (COVID-19). In: StatPearls [Internet]; [cited 2022 January 22]. Available from: http://www.ncbi.nlm.nih.gov/books/NBK554776;
5. Haleem A, Javaid M, Vaishya R. Effects of COVID-19 pandemic in daily life. Curr Med Res Pract. 2020; 10(2):78-9;